favipiravir - versus antiviral and associated therapy - for COVID-19 mild to moderate pdf   xlsx method abbreviations

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

efficacy endpoints 00

deaths 1.22 [0.66, 2.26]< 10%1 study (1/-)26.1 %NAnot evaluable crucial-
clinical improvement (time to event analysis only) 0.94 [0.75, 1.17]> 10%1 study (1/-)29.3 %NAnot evaluable important-
mechanical ventilation 1.62 [0.85, 3.08]< 10%1 study (1/-)7.2 %NAnot evaluable important-
ICU admission 1.23 [0.70, 2.18]< 10%1 study (1/-)23.7 %NAnot evaluable non important-

LoD: level of statistical demonstration: Statistically conclusive: statistically significant with a strict control of overall risk of type 1 error (statistically demonstrated), does not take into account the risk of bias; suggested: nominally statistically significant but without a strict control of overall risk of type 1 error; inconclusive: not nominally statistically significant; safety concerns;
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.